Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
一项随机、双盲、安慰剂对照试验,评估单剂量卡西利维单抗和伊维维单抗预防 COVID-19 的疗效和安全性,疗程为 8 个月。
期刊:Lancet Infectious Diseases
影响因子:31
doi:10.1016/S1473-3099(22)00416-9
Herman, Gary A; O'Brien, Meagan P; Forleo-Neto, Eduardo; Sarkar, Neena; Isa, Flonza; Hou, Peijie; Chan, Kuo-Chen; Bar, Katharine J; Barnabas, Ruanne V; Barouch, Dan H; Cohen, Myron S; Hurt, Christopher B; Burwen, Dale R; Marovich, Mary A; Musser, Bret J; Davis, John D; Turner, Kenneth C; Mahmood, Adnan; Hooper, Andrea T; Hamilton, Jennifer D; Parrino, Janie; Subramaniam, Danise; Baum, Alina; Kyratsous, Christos A; DiCioccio, A Thomas; Stahl, Neil; Braunstein, Ned; Yancopoulos, George D; Weinreich, David M